Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Simultaneous targeting of PD-1 and IL2Rβγ with radiation therapy to inhibit pancreatic cancer growth and metastasis - mouse blood T-cell metabolomics

ABSTRACT: Mice were orthotopically implanted with PK5L1940 cells then radiation therapy (8 Gy) administered 7 days post-implantation. PD1-IL2v and aCD25 dosed once per week beginning day 7 post-implantation. Blood was collected at time of sacrifice and sorted for CD8+ T-cells. The obtained T-cells were profiled by mass spectrometry-based metabolomics.

ORGANISM(S): Mouse Mus Musculus

TISSUE(S): T-cells

DISEASE(S): Cancer

SUBMITTER: Julie Haines

PROVIDER: ST002486 | MetabolomicsWorkbench | Tue Feb 21 00:00:00 GMT 2023

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

Simultaneous targeting of PD-1 and IL2Rβγ with radiation therapy to inhibit pancreatic cancer growth and metastasis - mouse serum metabolomics

Project description:Mice were orthotopically implanted with PK5L1940 cells then radiation therapy (8 Gy) administered 7 days post-implantation. PD1-IL2v and aCD25 dosed once per week beginning day 7 post-implantation. Serum was collected at time of sacrifice and profiled by mass spectrometry-based metabolomics to visualize changes in systemic metabolism in the mouse model.

2023-02-21 | ST002485 | MetabolomicsWorkbench

Simultaneous targeting of PD-1 and IL2Rβγ with radiation therapy to inhibit pancreatic cancer growth and metastasis - mouse spleen and lymph node T-cell metabolomics

Project description:Mice were orthotopically implanted with PK5L1940 cells then radiation therapy (8 Gy) administered 7 days post-implantation. PD1-IL2v and aCD25 dosed once per week beginning day 7 post-implantation. Spleen and associated lymph nodes were collected at time of sacrifice and sorted for CD8+ T-cells. The obtained T-cells were profiled by mass spectrometry-based metabolomics.

2023-02-21 | ST002487 | MetabolomicsWorkbench

Simultaneous targeting of PD-1 and IL2Rβγ with radiation therapy to inhibit pancreatic cancer growth and metastasis

Project description:Mice were orthotopically implanted with PK5L1940 cells then radiation therapy (8 Gy) administered 7 days post-implantation. PD1-IL2v and aCD25 dosed once per week beginning day 7 post-implantation. T-cells from spleen were obtained through sorting, cultured in the presence of 13C6 glucose for 6h, and glucose fluxes profiled via mass spectrometry-based metabolomics.

2023-02-21 | ST002489 | MetabolomicsWorkbench

Simultaneous targeting of PD-1 and IL2Rβγ with radiation therapy to inhibit pancreatic cancer growth and metastasis - T-cell tracing supernatants

Project description:C57BL/6 mice were orthotopically implanted with PK5L1940 cells. 8 Gy RT was administered 7 days post-implantation. PD1-IL2v and aCD25 dosed once per week beginning day 7 post-implantation. Spleens and lymph nodes were harvested 17 days post implantation and the sorted T-cells cultured in the presence of 13C6 glucose for 6h. This study contains longitudinal sampling of the cell culture supernatants.

2023-02-21 | ST002488 | MetabolomicsWorkbench

Simultaneous targeting of PD-1 and IL2RBY with radiation therapy to inhibit pancreatic cancer growth and metastasis

Project description:In patients with pancreatic ductal adenocarcinoma (PDAC), we show that response to radiation therapy (RT) is characterized by increased IL2R and IL2R expression, decreased ILR2 and exhaustion markers. The bispecific PD-1-targeted IL-2 variant (IL2v) immunocytokine with engineered IL-2 cis-targeted to PD-1 and abolished IL2R binding targets the activation of tumor-antigen specific T cells while rescuing them from Treg suppression. Using aPD1-IL2v in orthotopic PDAC KPC-driven tumor models, we show marked improvement in local and metastatic survival along with profound increase in tumor-infiltrating polyfunctional CD8 T cell subsets with a transcriptionally and metabolically active phenotype, and preferential activation of antigen-specific CD8 T cells. In combination with single dose RT, aPD1-IL2v treatment results in a robust, durable expansion of polyfunctional CD8 T cells, T cell stemness, tumor-specific memory immune response, NK cell activation, and decreased Tregs. These data show that the novel aPD1-IL2v, leads to profound local and distant response in PDAC.

2024-05-24 | PXD040266 | Pride

The immunocytokine PD1-IL2v overcomes resistance to tumor immunity, and synergizes with anti-PD-L1

Project description:Immunotherapies have shown remarkable, albeit tumor-selective therapeutic benefits in the clinic. Here we evaluated the effects of the immunocytokine PD1-IL2v in a mouse model of de novo pancreatic neuroendocrine cancer resistant to checkpoint and other immunotherapies. PD1-IL2v is a bi-specific molecule based on a bivalent PD-1 antibody, serving as a targeting moiety, fused to an immuno-stimulatory IL-2 variant (IL2v) to precisely deliver IL2v to PD-1+ T-cells in the tumor microenvironment. PD1-IL2v elicited dramatic infiltration by CD8 T cells, notably stem-like and effector memory T cells, resulting in tumor regression and enhanced survival in mice. Furthermore, combining anti-PD-L1 with PD1-IL2v sustained the response phase, improving therapeutic efficacy both by reprogramming immunosuppressive tumor-associated macrophages and tumor endothelial cells , and by enhancing TCR immune repertoire diversity. The data motivate consideration of clinical trials to evaluate the combination therapy of PD1-IL2v and anti-PD-L1, especially in immunotherapy-resistant tumors infiltrated with PD-1+ T stem-like CD8 T cells.

2023-01-10 | GSE197854 | GEO

Bulk RNA-Seq analysis of CD8+ T cells from treatment-naïve matched tumor-bearing lungs and spleens from the HKP1 orthotopic mouse lung adenocarcinoma model

Project description:To investigate how gene expression profiles change in CD8+ T cells based on time, tumor burden, and tissue localization, we orthotopically implanted the mouse lung adenocarcinoma HKP1 cell line expressing luciferase into syngeneic C57BL/6 mice by tail vein injections. Tumor growth was monitored by bioluminescence imaging. A separate cohort of mice received no tumor implantation. At days 7, 17, and 24 post tumor implantation, mice were euthanized and CD8+ T cells sorted from tumor-bearing lungs and spleens, or matched naive lungs and spleens. We then performed gene expression profiling analysis using data obtained from RNA-seq of sorted cells, comparing across time, tumor burden, and tissue localization.

2023-10-19 | GSE218141 | GEO

Gene expression profiles of human Natural Killer Cells, unstimulated and stimulated with IPH6501, a tetraspecific NK cell engager (NKCE).

Project description:The impact of IPH6501 treatment on the transcriptome of blood NK cells was dissequed using scRNA seq analysis. Unsupervised analysis of human blood NK cells revealed significant transcriptomic changes across NK1, NK2, and NK3 cell subsets following in vitro stimulation by CD20-NKCE-IL2v, indicating that treatment affect all NK cell subsets. Stimulation with the CD20-NKCE-IL2v led to the emergence of another NK cell cluster characterized by a signature resembling cytokine-induced memory-like (CIML) NK cells similar to that found in NK cells activated by IL-2/IL-15/IL-12/IL-18. This population was observed at both 4- and 24-hours post-stimulation.

2024-08-07 | GSE273867 | GEO

Single-cell RNA-seq and TCR-seq of Panc02-Fluc model with vehicle, anti PD1-IL2v, PD1, FAP-IL2v and PD1+FAP-IL2v treatment

Project description:Differentiating PD-1 + TCF-1 + stem-like CD8 T cells towards a distinct effector T cell population with enhanced anti-tumor and anti-viral efficacy by delivering an engineered IL-2 variant through PD-1 mediated cis-targeting; Single time point at termination (day 3 after 2nd Ab therapy); Tumor model: Panc02-Fluc pancreatic subcutaneous; Groups 0.5 mg/kg muPD-1-IL2v, 10 mg/kg muPD1, 1.5 mg/kg muFAP-IL2v, 10 mg/kg muPD1 + 1.5 mg/kg muFAP-IL2v, Vehicle; scRNA-seq analysis including feature barcoding and TCR-seq.

2022-06-13 | E-MTAB-11773 | biostudies-arrayexpress

PD-1+TCF-1+ stem-like CD8 T cells differentiate into effector T cells with enhanced anti-tumor and viral efficacy upon PD-1 cis-targeted IL-2R-agonism”

Project description:Here we show that IL-2Rbg-biased agonists are unable to preferentially expand better effector T cells in cancer models, and describe PD1-IL2v, a novel immunocytokine, that overcomes the need for CD25 binding by docking in cis to PD-1. In cis binding of PD1-IL2v to PD-1 and IL-2Rbg on the same cell recovers the ability to differentiate stem-like CD8 T cells into better effectors in the absence of CD25 binding in both chronic infection and cancer models, and provides superior efficacy.

2022-07-21 | GSE208556 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data